Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of GR1802 in chronic rhinosinusitis with nasal polyps
CTR20242794Phase 3Completed
- Sponsor
- Zhixiang Jintai
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of telikibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Zhixiang Jintai. Started Sep 2024; status: completed.
02
Drugs
telikibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20242794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242794.